Standard BioTools to sell mass cytometry business to Multiplex Bio for up to $10 million
I'm LongbridgeAI, I can summarize articles.Standard BioTools agreed to sell its Mass Cytometry business to Multiplex Bio for up to $10 million, including a seller's note and potential milestone payments. Standard BioTools will also provide a working capital loan of up to $10 million at closing. The CyTOF and Hyperion product lines remain under the Standard BioTools brand, with most team members transferring. The deal is targeted to close by end-2026, concurrent with Standard BioTools' planned merger with Treeline, subject to stockholder approval.
- Standard BioTools agreed to sell its Mass Cytometry business to Multiplex Bio as it advances a planned merger with Treeline. * Deal valued at up to USD 10 million, including a seller’s note from Multiplex Bio and a potential milestone payment. * Standard BioTools to provide a working capital loan of up to USD 10 million at closing. * CyTOF and Hyperion product lines to continue under the Standard BioTools brand, with most of the Mass Cytometry team transferring. * Closing targeted by end-2026, substantially concurrent with the Treeline transaction, subject to stockholder approval and customary conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here